Rifaximin 3 Times/Day for Non-constipation IBS
Summary
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
Study Design
Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Conditions
Non-constipation Irritable Bowel Syndrome
Intervention
Rifaximin, Placebo
Location
Anniston
Alabama
United States
36207
Status
Completed
Source
Salix Pharmaceuticals
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00724126
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Colonic Diseases, Functional
Chronic or recurrent colonic disorders without an identifiable structural or biochemical explanation. The widely recognized IRRITABLE BOWEL SYNDROME falls into this category.
Irritable Bowel Syndrome
A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
Bisacodyl
A diphenylmethane stimulant laxative used for the treatment of constipation and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)
Short Bowel Syndrome
A malabsorption syndrome resulting from extensive operative resection of the SMALL INTESTINE, the absorptive region of the GASTROINTESTINAL TRACT.
Echogenic Bowel
A PRENATAL ULTRASONOGRAPHY finding of excessively dense fetal bowel due to MECONIUM buildup.
Clinical Trials
In this study the investigators aim to compare the efficacy of neomycin to a combination of rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test. Thi...
This is placebo-controlled study of three rifaximin doses in patients with DIBS. Subjects will be randomized to receive daily doses of placebo BID, rifaximin 275 mg BID, rifaximin 550 mg...
Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with irritable bowel syndrome with constipation (IBS-C). The primary efficacy p...
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to determine the safety and efficacy of linaclotide administered to patients with Irritable Bowel Syndrome with Constipation (IBS-C).
Rifaximin for the Treatment of Irritable Bowel Syndrome
We have recently shown that the majority of patients with irritable bowel syndrome (IBS) have an abnormal lactulose breath test to suggest the presence of bacterial overgrowth of the small...
PubMed Articles
Rifaximin therapy for patients with irritable bowel syndrome without constipation.
Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS.
Rifaximin for Irritable Bowel Syndrome without Constipation.
To the Editor: Two issues are major drawbacks of the study by Pimentel et al. (Jan. 6 issue)(1) on rifaximin therapy for patients with irritable bowel syndrome (IBS) without constipation. First, the d...
Rifaximin for Irritable Bowel Syndrome without Constipation.
To the Editor: Two issues are major drawbacks of the study by Pimentel et al. (Jan. 6 issue)(1) on rifaximin therapy for patients with irritable bowel syndrome (IBS) without constipation. First, the d...
Rifaximin for Irritable Bowel Syndrome without Constipation.
To the Editor: Two issues are major drawbacks of the study by Pimentel et al. (Jan. 6 issue)(1) on rifaximin therapy for patients with irritable bowel syndrome (IBS) without constipation. First, the d...
